QURE Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$64.87median target· current $39.70 (+63.4%)13 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 27.93
EPS (TTM)$-3.49-18.2% YoY
Profit margin0.0%HEALTHCARE
Market cap$2.77BMid cap
Valuation
- Forward P/E
- 27.93
- PEG ratio
- 0.00
- P/B
- 18.53
- P/S (TTM)
- 152.95
- EV/EBITDA
- 1.40
Profitability & growth
- ROE (TTM)
- -228.2%
- Operating margin
- -1321.0%
- Revenue growth YoY
- 127.3%
- Dividend yield
- —
- Beta
- 0.90
Last earnings
May 5, 2026 · Estimate $-0.75 · Reported $-0.73
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Uniqure NV
Company profileuniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- PAASHEUVELWEG 25, AMSTERDAM, NETHERLANDS
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$2.77B
Shares outstanding$68.8M
52W high$71.50
52W low$8.73
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent